1-棕榈酰-2-油酰基磷脂酰乙醇胺 | 10015-88-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: 1-棕榈酰-2-油酰基磷脂酰乙醇胺
• 中文别名: 1-棕榈酰基-2-油酰基磷脂酰乙醇胺(POPE)
• 英文名称: POPE
• 英文别名: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine；1-Palmitoyl-2-oleoylphosphatidylethanolamine；2-azaniumylethyl [3-hexadecanoyloxy-2-[(Z)-octadec-9-enoyl]oxypropyl] phosphate
• CAS: 10015-88-0
• 化学式: C₃₉H₇₆NO₈P
• 分子量: 718.008
• InChiKey: FHQVHHIBKUMWTI-ZCXUNETKSA-N

物化性质

• 沸点：
  741.6±70.0 °C(Predicted)
• 密度：
  1.009±0.06 g/cm3(Predicted)
• 碰撞截面：
  263.99 Ų [M-H]- [CCS Type: TW, Method: calibrated with phosphatidylcholines (ESI+) and phosphatidylethanolamines (ESI-) doubly charged cardiolipins calibrated with poly-DL-alanine]

计算性质

• 辛醇/水分配系数(LogP)：
  10.4
• 重原子数：
  49
• 可旋转键数：
  40
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  1-棕榈酰-2-油酰基磷脂酰乙醇胺 在 吡啶 、 hydroxylamine-O-sulfonic acid 作用下， 生成 C₃₉H₇₇N₂O₈P
  参考文献：
  名称：

  用于探测不饱和脂质异构体和准确相对定量的氮丙啶脂质质量标签**

  摘要：

  开发了一种基于氮丙啶的等压标记策略，用于脂质准确的相对定量、异构体鉴定和电离效率的提高。该策略允许在不使用脂质内标和脂质双键位置异构体表征的情况下进行多重分析。我们设想它将加速发现用于早期疾病诊断、进展监测和治疗反应预测的脂质生物标志物。

  DOI：

  10.1002/anie.202207098

文献信息

• Simultaneous gene editing and haploid induction
  申请人：Syngenta Participations AG

  公开号：US10285348B2

  公开（公告）日：2019-05-14

  The presently disclosed subject matter relates to using a haploid inducing line (whether existing or created) and transforming the haploid line so that it encodes cellular machinery capable of editing genes. The transformed haploid inducing line is used as a parent in a cross between two plants. During pollination, the parental gametes fuse to form an embryo; and the gene editing machinery is also delivered to the embryo at this time. During embryonic development, one set of parental chromosomes are lost, and the gene editing machinery operates on the remaining set of chromosomes. Thus, at least one haploid progeny with edited genes is produced from the cross.

  目前公开的主题涉及使用单倍体诱导系（无论是现有的还是已创建的），并对单倍体诱导系进行转化，使其编码能够编辑基因的细胞机器。转化后的单倍体诱导系在两株植物的杂交中用作亲本。在授粉过程中，亲本配子融合形成胚胎；此时，基因编辑机器也被输送到胚胎中。在胚胎发育过程中，亲本的一组染色体丢失，基因编辑机制在剩余的一组染色体上运行。因此，杂交后至少会产生一个带有编辑基因的单倍体后代。
• Inhibitors for targeting flaviviruses
  申请人：National Technology & Engineering Solutions of Sandia, LLC

  公开号：US11197854B1

  公开（公告）日：2021-12-14

  The present invention relates to methods for identifying candidate therapeutics for a disease caused by a viral envelope protein. In particular, the method can include contacting a test envelope protein with the candidate and determining its activity.

  本发明涉及确定由病毒包膜蛋白引起的疾病的候选疗法的方法。特别是，该方法可包括将测试包膜蛋白与候选药物接触并确定其活性。
• Synthesis and structural characterization of carboxyethylpyrrole-modified proteins: mediators of age-related macular degeneration
  作者：Liang Lu、Xiaorong Gu、Li Hong、James Laird、Keeve Jaffe、Jaewoo Choi、John Crabb、Robert G. Salomon

  DOI：10.1016/j.bmc.2009.09.009

  日期：2009.11

  Protein modifications in which the e-amino group of lysyl residues is incorporated into a 2-(omega-carboxy-ethyl)pyrrole (CEP) are mediators of age-related macular degeneration (AMD). They promote both angiogenesis into the retina ('wet AMD') and geographic retinal atrophy ('dry AMD'). Blood levels of CEPs are biomarkers for clinical prognosis of the disease. To enable mechanistic studies of their role in promoting AMD, for example, through the activation of B- and T-cells, interaction with receptors, or binding with complement proteins, we developed an efficient synthesis of CEP derivatives, that is especially effective for proteins. The structures of tryptic peptides derived from CEP-modified proteins were also determined. A key finding is that 4,7-dioxoheptanoic acid 9-fluorenylmethyl ester reacts with primary amines to provide 9-fluorenylmethyl esters of CEP-modified proteins that can be deprotected in situ with 1,8-diazabicyclo[5.4.0]undec-7-ene without causing protein denaturation. The introduction of multiple CEP-modifications with a wide variety of CEP: protein ratios is readily achieved using this strategy. (C) 2009 Elsevier Ltd. All rights reserved.
• HAPLOID INDUCTION COMPOSITIONS AND METHODS FOR USE THEREFOR
  申请人：Syngenta Participations AG

  公开号：EP3377615A1

  公开（公告）日：2018-09-26
• SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION
  申请人：Syngenta Participations AG

  公开号：EP3547825A1

  公开（公告）日：2019-10-09